Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025

Structure Therapeutics Inc.

2025-Q2 EPS reported -$0.63

Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.
Cash, equivalents, and short-term investments $786.5M; expected to fund operations through at least 2027.
Topline data from aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.
Three new aleniglipron studies initiated: maintenance switching, body composition, T2DM, with enrollment Q3/Q4 2025.
ACCG-2671 (oral amylin) Phase 1 initiation planned by year-end 2025; preclinical data presented.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.